Related by context. All words. (Click for frequent words.) 78 receiving chemoradiation therapy 72 metastatic malignant 72 papillary renal cell carcinoma 71 recurrent glioblastoma multiforme 71 ulcerative mucositis 70 recurrent genital herpes 70 Cutaneous T 69 CYT# potent vascular disrupting 69 velafermin 69 Adjuvant Treatment 69 Myelodysplastic Syndrome MDS 69 Relapsed Refractory 69 Ribavirin causes 69 Soft Tissue Sarcoma 69 vapreotide acetate 69 hyperphenylalaninemia HPA due 68 Follicular Lymphoma 68 Severe Sepsis 68 polycythemia vera essential thrombocythemia 68 severe neutropenia 68 essential thrombocythemia ET 68 cutaneous T 68 external genital lesions 68 Phase 2b Clinical Trial 68 tumor lysis syndrome 68 dasatinib Sprycel ® 68 complement inhibitor eculizumab 68 Glioblastoma Multiforme 68 Initiate Phase 68 ara C 68 SPRYCEL ® 68 Complicated Skin 68 stage IIIB 68 Oral Fingolimod 68 cervical vulvar 68 leukemia AML 68 assessing T DM1 68 PAOD 68 hypereosinophilic syndrome 68 non splenectomized 68 Metastatic Prostate Cancer 67 kidney urologic 67 Advanced Melanoma 67 acute GvHD 67 evaluating picoplatin 67 metastatic colorectal carcinoma 67 alfa 2a 67 Cerebril TM 67 Chronic Hepatitis C 67 myelodysplastic myeloproliferative diseases 67 chronic eosinophilic leukemia 67 containing granisetron 67 novel VDA molecule 67 PNP inhibitor 67 8mg/kg 67 Idiopathic Pulmonary Fibrosis 67 docetaxel Taxotere ® 67 BCG refractory carcinoma 67 Phase IIb Trial 67 Toxicities 67 nephrotoxicity 67 idiopathic thrombocytopenic purpura ITP 67 Relapsing Remitting Multiple Sclerosis 67 keloid scarring 67 invasive aspergillosis 67 IN PATIENTS WITH 67 chronic myeloid 67 Myelofibrosis 67 post herpetic neuralgia PHN 67 rheumatoid arthritis RA psoriatic 67 angioneurotic edema 67 steroid refractory GvHD 67 refractory chronic lymphocytic 67 2 methoxyestradiol 67 CTAP# Capsules 67 Vitrasert R 67 MAGE A3 ASCI 67 myocardial infarction ventricular fibrillation 67 Metastatic Colorectal Cancer 67 Chronic Myelogenous Leukemia CML 67 antibody MAb 67 Prolongs Survival 67 FUSILEV enhances 67 metastatic GIST 67 colorectal adenoma 66 neutropenia dehydration dyspnea 66 thrombocytopenia neutropenia 66 active ankylosing spondylitis 66 relapsed Acute Myeloid 66 palifermin 66 Chronic Sinusitis 66 oral mucositis OM 66 Pharmacokinetics PK 66 oral prodrug 66 non metastatic osteosarcoma 66 febrile neutropenia 66 recurrent metastatic 66 relapsing remitting MS RRMS 66 grade cervical intraepithelial 66 brand ciclesonide HFA 66 acute GVHD 66 Kit CD# positive 66 HBeAg negative 66 hypophosphatemia 66 atherothrombotic events 66 Advanced Renal Cell 66 diabetic gastroparesis 66 generation purine nucleoside 66 neurologic progression 66 dependent kinase inhibitor 66 Newly Diagnosed Multiple Myeloma 66 herpes zoster shingles 66 delayed onset CINV 66 Pivotal Phase 66 receptor tyrosine kinase inhibitor 66 Lymphocytic 66 relapsing multiple sclerosis 66 Recurrent Glioblastoma 66 refractory gout 66 selective phosphodiesterase 66 included exfoliative dermatitis 66 eosinophilic asthma 66 Randomized Phase 66 sodium thiosulfate STS 66 leukemia ALL 66 TO AVOID PREGNANCY WHILE 66 esophageal carcinoma 66 erlotinib Tarceva ® 66 somatostatin analog 66 Relapsing Multiple Sclerosis 66 tumors GIST 66 R Saizen R 66 chronic rheumatic 66 Trial Evaluating 66 paclitaxel poliglumex 66 Denufosol 66 Meets Primary Endpoint 66 Vicinium TM 66 dual endothelin receptor antagonist 66 Hormone Refractory Prostate Cancer 66 TNF Tumor Necrosis Factor 66 transthyretin TTR mediated amyloidosis 66 arthritis PsA 66 chemotherapy induced neutropenia 66 Epratuzumab 66 Thromboembolism 66 forodesine 66 methylnaltrexone bromide 66 renal failure interstitial lung 66 metastatic malignant melanoma 66 Amgen Neulasta R 66 Severe VOD 66 Stage IIB 66 II Clinical Trial 66 Phase 2b Trial 66 relapsed MM 65 chemoradiation therapy 65 Peginterferon alfa 2b 65 Kamada AAT 65 receiving XGEVA 65 Decitabine 65 treatment naive genotype 65 Peginterferon 65 monoclonal antibody IgG1 Mab 65 biologic DMARD 65 Testosterone MDTS ® 65 rheumatoid arthritis osteoarthritis ankylosing 65 familial amyloidotic polyneuropathy FAP 65 venous thromboembolic events 65 Pivotal Phase III 65 gemcitabine Gemzar ® 65 Degarelix 65 Metastatic Melanoma 65 NSAID induced 65 corticosteroid therapy 65 metastatic pancreatic 65 See CONTRAINDICATIONS 65 lymphoid blast 65 EXJADE 65 Pemetrexed 65 Bronchiectasis 65 cell lymphoma CTCL 65 polycythemia vera PV 65 metastatic colorectal 65 Ranolazine 65 HuMax EGFr 65 oropharyngeal candidiasis OPC 65 FluCAM arm 65 biliary tract cancer 65 #mg BID [001] 65 opioid induced constipation OIC 65 Initiates Phase II 65 Oral Mucositis 65 Plaque Psoriasis 65 metastatic androgen independent 65 ACTEMRA TM 65 adalimumab Humira 65 VEGFR2 inhibitor 65 immune thrombocytopenic purpura ITP 65 basiliximab 65 chronic idiopathic thrombocytopenic purpura 65 catheter occlusion 65 neutropenic sepsis 65 Phase IIa Clinical Trial 65 Acute Myeloid Leukaemia AML 65 Study Evaluating 65 erythematosus 65 cutaneous squamous cell carcinoma 65 piperacillin tazobactam 65 Safinamide 65 SSc 65 BRIM2 65 Vitrasert ® 65 Hsp# Inhibitor 65 postoperative AF 65 postherpetic neuralgia PHN 65 LymphoStat B belimumab 65 Achieves Primary Endpoint 65 TransVax 65 occlusion PAO 65 proctitis 65 CLL SLL 65 gastrointestinal mucositis 65 metastatic gastric 65 Diffuse Large B 65 Improves Outcomes 65 oral mucositis 65 Nilotinib 65 systemic anaplastic large 65 Omacetaxine 65 Infusion Reactions Severe 65 PEGylated interferon beta 1a 65 Janus kinase 65 CYP#A# CYP#D# 65 acute mania 65 aplastic anemia AA 65 Veno Occlusive Disease 65 intraepithelial neoplasia 65 exocrine pancreatic insufficiency EPI 65 Dose Ranging Study 65 pulmonary hypertension PH 65 Demonstrates Significant 65 steroid refractory ulcerative 65 hour bronchodilation 65 Kinoid 65 AA Amyloidosis 65 ribavirin RBV 65 delayed CINV 65 cisplatin chemotherapy 65 Proxinium TM 65 intravesical infusion therapy 65 completely resected 65 TTR amyloidosis 65 Malignant Melanoma 65 MELAS 65 sunitinib Sutent ® 65 monoclonal antibody conjugated 65 acute myeloid 65 prokinetic agent 65 TORISEL 65 oral methylnaltrexone 65 stage IIIb IV 65 formerly LymphoStat B 65 Unstable Angina 65 acute radiation enteritis 65 BARACLUDE ® 65 chronic thromboembolic pulmonary 65 Second Pivotal Phase 64 chronically immunosuppressed solid 64 Initiates Enrollment 64 Mg Uk 64 AAG geldanamycin analog 64 sorafenib tablets 64 iobenguane 64 Telintra 64 torsade de pointes 64 NMIBC 64 Renal Impairment 64 Fludarabine 64 RhD positive 64 hepatorenal syndrome 64 diarrhea predominant irritable 64 systemic lupus erythematosus psoriasis 64 Demonstrates Positive 64 Nebulized 64 Refractory Hodgkin Lymphoma 64 Hepatocellular Carcinoma HCC 64 anterior uveitis 64 Phase III Clinical Trial 64 invasive candidiasis 64 estramustine 64 humanized interleukin 6 64 Personalized Immunotherapy 64 NASH Huntington 64 By JENNIFER LEARN 64 acute peripheral arterial 64 reduce serum phosphate 64 minimally symptomatic metastatic castrate 64 biochemical relapse 64 advanced hepatocellular carcinoma 64 Treatment Naive Patients 64 Malignant Glioma 64 5 HT2A inverse 64 gout flares 64 Initiates Phase 64 Simulect 64 esophageal candidiasis 64 thalidomide Thalomid 64 HBeAg positive patients 64 leucopenia 64 ANCA associated 64 Synta Announces 64 treat chronic sinusitis 64 Hepatocellular Carcinoma 64 bone marrow reticulin deposition 64 Cyclophosphamide 64 transplantation HCT 64 Major Depressive Disorder MDD 64 Randomized Phase II 64 Prospective Randomized 64 Adjuvant Chemotherapy 64 Abrupt discontinuation 64 hypertrichosis occurred 64 cutaneous melanoma 64 Immunotherapeutic 64 Acute Myeloid Leukemia AML 64 Zorbtive TM 64 chemoradiotherapy 64 Receives Orphan Drug Designation 64 induce orthostatic hypotension 64 Romiplostim 64 essential thrombocythemia 64 Known hypersensitivity 64 investigational monoclonal antibody 64 Xyfid TM 64 Castration Resistant Prostate Cancer 64 Hydroxyurea 64 carcinoma mCRC 64 accompanying electrolyte abnormalities 64 mycophenolate mofetil MMF 64 Acute Bacterial Sinusitis ABS 64 MGd 64 deep venous thromboses 64 induced macular edema 64 cervical cancer precancerous 64 Mg Usa 64 pheochromocytoma 64 Squamous Cell Carcinoma 64 Glufosfamide 64 FOLFOX6 64 lead Aganocide compound 64 variceal hemorrhage 64 moderate renal impairment 64 Shows Promise Against 64 intravascular hemolysis 64 Polyneuropathy 64 nucleotide analog 64 Neutropenia 64 dasatinib Sprycel 64 Erythropoietic therapies may 64 PEGylated anti 64 Single Dose 64 docetaxel Taxotere R 64 HCV Genotype 64 NicVAX TM 64 Antitumor Activity 64 pancreatic prostate 64 Is Well Tolerated 64 Mantle Cell Lymphoma 64 pDC 64 Patients Treated With 64 Chronic Renal Failure 64 Cell Lymphoma CTCL 64 Novel Oral 64 Atypical Hemolytic Uremic Syndrome 64 albiglutide 64 Adenoviral 64 HeFH 64 Kepivance 64 Completes Patient Enrollment 64 glucocorticoid induced osteoporosis 64 acetonide FA 64 Orally administered 64 SinuNase TM 64 PANVAC VF 64 myelofibrosis polycythemia vera 64 lucinactant 64 Catheter Associated 64 hypercalcemia 64 morphometric vertebral fractures 64 pan histone deacetylase 64 MKC# MT 64 INSPIRE Trial Phase III 64 Pafuramidine 64 hematologic toxicity 64 SNT-MC#/idebenone 64 chronic granulomatous disease 64 Hypotension 64 prostate cancer mCRPC 64 IAP inhibitor 64 Natalizumab 64 parathyroid carcinoma 64 recurrent malignant glioma 64 Infected Patients 64 peripheral arterial occlusive disease 64 CML CP 64 cisplatin gemcitabine 64 Hodgkin lymphoma HL 64 ELACYT 64 resistant hormone refractory 64 Node Positive 64 ® lenalidomide 64 Protease Inhibitor 64 oral nucleoside analogue 64 MCyR 64 huN# DM1 64 plus gemcitabine 64 evaluating T DM1 64 Monotherapy 64 mitoxantrone plus 64 Melphalan 64 idiopathic thrombocytopenic purpura 64 Bronchopulmonary Dysplasia 64 EGFR TKI 64 Panzem R 64 vidofludimus 64 cell carcinoma RCC 64 chronic immune thrombocytopenic 64 Relapsed Refractory Multiple Myeloma 64 severe hypersensitivity reactions 64 calcineurin inhibitor 64 Adalimumab 64 Leukemias 64 ankylosing spondylitis AS 64 Heterozygous Familial Hypercholesterolemia 64 Primary Hypercholesterolemia 64 TAXOTERE ® 64 bronchial hyperresponsiveness 64 Myelodysplastic Syndrome 64 elevated transaminases 64 Seasonal Allergic Rhinitis 64 JAK2 Inhibitor 64 albiglutide currently 64 Bayer HealthCare Onyx Pharmaceuticals 64 refractory NSCLC 64 Enzastaurin 64 Non Alcoholic Steatohepatitis 64 5 fluorouracil leucovorin 64 Commence Phase 64 indolent follicular non 64 immunocompetent patients 64 peritumoral brain edema 64 B Cell Lymphoma 64 FOLOTYN ® 64 Acute myeloid leukemia 63 Chemotherapy Induced 63 heFH 63 Community Acquired Pneumonia 63 Metastases 63 Parathyroid Hormone 63 ALT normalization 63 vWF 63 Dasatinib 63 plus prednisone prednisolone 63 treat dysmenorrhea 63 metastatic carcinoma 63 Ischemic 63 Thromboembolic 63 autosomal recessive disorder 63 R lenalidomide 63 hormone refractory metastatic prostate 63 Irinotecan 63 lymphocytosis 63 Chronic Myeloid Leukemia 63 receiving VELCADE 63 Previously Treated 63 refractory cutaneous T 63 post surgical adhesions 63 Adjunctive Therapy 63 recurrent glioma 63 Pneumococcal Vaccine 63 Previously Untreated 63 de novo kidney transplant 63 Silodosin 63 lenalidomide Revlimid R 63 Testosterone MDTS R 63 GOUT 63 Vascular Disrupting Agent 63 DG# compounds targeting 63 acute onset CINV 63 disease GERD 63 Idiopathic Thrombocytopenic Purpura ITP 63 gastric carcinoma 63 subependymal giant cell 63 Metabolic Efficiency 63 Successfully Treated 63 purpura ITP 63 Forodesine HCl 63 unresectable stage 63 Unresectable 63 4mg/kg 63 PEG IFN 63 ritonavir boosted 63 hemorrhagic cystitis 63 alkylating agent 63 non nucleoside inhibitor 63 Bosutinib 63 posaconazole 63 5 Fluorouracil 63 evaluating tivozanib 63 pancreas esophagus 63 5 FU leucovorin 63 trimethoprim sulfamethoxazole 63 moderate hepatic impairment 63 pegIFN 63 â ‰ ¥ 63 cervical carcinoma 63 Intravitreal 63 PARGLUVA 63 ketolide antibiotic 63 Crofelemer budesonide foam 63 demonstrated antitumor activity 63 Acute Ischemic Stroke 63 metastatic neuroendocrine tumors 63 gastrointestinal stromal 63 STRIDE PD 63 FDA APPROVES 63 Torisel 63 underlying vasculopathy 63 including thyroiditis RA 63 Sezary syndrome 63 Initiated Phase 63 3 registrational trial 63 Phase III Trial 63 Naive Patients 63 Thrombocytopenia 63 multiple myeloma MM 63 Platinol ® 63 cinacalcet 63 vaginally administered lidocaine 63 Hepatitis C Genotype 63 Chronic Lymphocytic Leukemia 63 FOLFIRI alone 63 particularly SANCTURA XR 63 Neulasta ® 63 VP# [004] 63 Inhalation Solution 63 phase IIb study 63 Lupus nephritis 63 Sapacitabine 63 gastrointestinal stromal tumor 63 Combination REOLYSIN R 63 denileukin diftitox 63 diarrhea fatigue asthenia 63 gastrointestinal stromal tumors GIST 63 Adjuvant Therapy 63 Thrombotic 63 advanced carcinoid 63 oral beclomethasone dipropionate 63 trial evaluating PRX# 63 unresectable locally advanced 63 Cancer Incidence Mortality 63 Rigel R# 63 modified glutathione analog 63 desvenlafaxine succinate 63 Vidofludimus 63 deferiprone 63 Mycophenolate Mofetil 63 Graft Versus Host 63 LAB CGRP 63 mycophenolate mofetil 63 colorectal carcinoma 63 hypophosphatasia 63 endometrial hyperplasia 63 virus HCV protease inhibitor 63 CIMZIA TM 63 Vidaza azacitidine 63 Zevalin R Ibritumomab 63 Peginterferon Alfa 2a 63 Interferon beta 1b 63 headache abdominal pain 63 oral mTOR inhibitor 63 achieved ACR# 63 Occlusive Disease 63 adjuvant GIST 63 dysplastic lesions 63 HGS ETR1 mapatumumab 63 Recombinant Human 63 nucleoside analog 63 SGPT 63 Hospital Acquired Pneumonia 63 Certolizumab pegol 63 pain palliation 63 weekly subcutaneous injections 63 comparator arm 63 Intravenous immunoglobulin 63 TAXOTERE R 63 antibody titer 63 BENICAR HCT 63 hypersensitivity reaction 63 saline placebo 63 mild renal insufficiency 63 Acute Exacerbations 63 systemic corticosteroid 63 dilated cardiomyopathy DCM 63 Bezielle 63 budesonide foam 63 Critical Limb Ischemia CLI 63 Phase #b/#a clinical 63 alpha1 antitrypsin deficiency 63 cholangiocarcinoma 63 PEGylated Fab fragment 63 Confirmatory Phase 63 dose escalation clinical 63 Plus Ribavirin 63 Inhalation Aerosol 63 BENLYSTA TM 63 riociguat 63 sodium glucose cotransporter 63 R roscovitine CDK cyclin 63 cytomegalovirus infection 63 lintuzumab SGN 63 Pivotal Trial 63 overt hepatic encephalopathy HE 63 hepatocellular carcinoma liver 63 Dupuytren Contracture 63 Acute Myelogenous Leukemia AML 63 personalized cellular immunotherapy 63 cetuximab Erbitux R 63 CMV seropositive 63 brivanib 63 FOLFOX6 chemotherapy regimen 63 sunitinib Sutent 63 inhaled liposomal ciprofloxacin 63 Hematologic 63 Phase Ib clinical 63 Microalbuminuria 63 primary humoral immunodeficiency 63 Thrombotic thromboembolic complications 63 NAGS deficiency 63 treat lupus renal 63 lexidronam injection 63 Acute Radiation Syndrome ARS 63 Associated Adipose Redistribution 63 Investigational Treatment 63 Idiopathic Pulmonary Fibrosis IPF 63 Bosentan 63 Unstable angina 63 Sudhir Agrawal D.Phil 63 Hycamtin ® 63 icatibant 63 acyclovir Lauriad R 63 superficial bladder cancer 63 See WARNINGS 63 depsipeptide 63 targeted radiotherapeutic 63 Candida infection 63 MULTAQ 63 dextromethorphan quinidine 63 Fx #A 63 Oral Formulation 63 Azacitidine 63 vaginal candidiasis 63 CDAD Clostridium difficile 63 Tarceva TM 63 HDAC Inhibitor 63 Fludara ® 63 Successfully Completes Phase 63 5-FU/LV 63 gastrointestinal stromal tumor GIST 63 secondary hyperparathyroidism 63 Annamycin 63 Pulmonary Arterial Hypertension 63 CHOP chemotherapy 63 dihydroergotamine DHE 63 hyperplasia BPH 63 hypomagnesemia 63 R abatacept 63 histone deacetylase HDAC inhibitor 63 developing Bicifadine serotonin 63 renal flares 63 liver decompensation 63 Pivotal Study 63 mRCC 63 Efficacy Trial 63 variceal bleeding 63 Chronic Heart Failure 63 Chronic Lymphocytic Leukemia CLL 63 oral ridaforolimus 63 inducible nitric oxide synthase 63 documented candidiasis 63 keloid scarring treatment 63 immune modulator 63 mucosal inflammation 63 grade squamous intraepithelial 63 stage IIIb 63 recurrent VTE 63 administered concomitantly 63 myeloproliferative diseases 63 Cimzia TM 62 Cerebral Amyloid Angiopathy 62 Myelodysplastic Syndromes 62 immunomodulatory therapy 62 limiting toxicity DLT 62 unresectable liver cancer 62 orally administered synthetic retinoid 62 including eniluracil ADH 62 benign prostatic hyperplasia enlarged 62 First Patient Dosed 62 CRMD# 62 XL# SAR# 62 grade cervical dysplasia 62 prednisone prednisolone plus 62 Diabetic Nephropathy 62 simplex virus 62 Chronic Hepatitis B 62 cobiprostone 62 HBeAg negative patients 62 DEB# 62 Peripheral Arterial 62 nucleoside naive 62 aldehyde dehydrogenase ALDH2 deficiency 62 Angioedema 62 administering XIFAXAN 62 Percutaneous Transluminal Coronary Angioplasty 62 Accelerated Partial Breast Irradiation 62 Randomized Double blind 62 ATTR 62 neurological manifestations 62 Completes Enrollment 62 Interferon beta 1a 62 Frozen Shoulder syndrome Adhesive 62 Prednisone Against Refractory 62 humanized therapeutic 62 heparin induced thrombocytopenia 62 Anthracycline 62 Pegylated Liposomal Doxorubicin 62 benzoic acid hyoscyamine sulfate 62 EVIZON TM 62 Clinical Trial Evaluating 62 Philadelphia Chromosome Positive 62 interferon ribavirin 62 haematologic 62 Adjuvant chemotherapy 62 oral candidiasis 62 lichen planus 62 Phase 2b Study 62 vinorelbine tartrate 62 LUX Lung 62 nonmetastatic 62 Presents Positive 62 TLK# 62 sapropterin dihydrochloride 62 ISTODAX ® 62 Prodarsan R 62 salmeterol fluticasone 62 CIMZIA R 62 AML MDS 62 Carcinoma 62 Ofatumumab 62 Folfox 62 intranasal formulation 62 cramping abdominal pain 62 Evoltra ® 62 Fast Track Status 62 Mitomycin C 62 voriconazole 62 abacavir lamivudine 62 pralatrexate injection folate analogue 62 oral rivaroxaban 62 corticosteroid dose 62 varicella zoster virus VZV 62 nephropathic cystinosis cystinosis 62 Sprycel dasatinib 62 Treating Chronic 62 beclomethasone dipropionate 62 telaprevir dosed 62 squamous cell carcinoma SCC 62 baminercept 62 MVA MUC1 IL2 62 Chronic lymphocytic leukemia 62 lymphoma CTCL 62 pediatric Crohn disease 62 Herpes Zoster 62 acyclovir Zovirax 62 imatinib Gleevec ® 62 measurable tumor regressions 62 Cell Lymphoma 62 Tyrosine Kinase Inhibitor 62 Fluorouracil 62 relapsed ALL 62 Chronic HCV 62 investigational immunotherapy 62 CMV disease 62 allogeneic hematopoietic stem cell 62 oral deforolimus 62 Clinical Trial Results 62 Oral Calcitonin 62 TRO# 62 Patients Treated 62 Pegylated Interferon 62 Diamyd r 62 interferon gamma 1b 62 triggers apoptosis programmed 62 murine model 62 histologic subtype 62 orally administered inhibitor 62 palmar plantar 62 BRSV 62 inflammatory acne 62 phase IIb clinical 62 hereditary deficiency 62 octreotide LAR 62 Replacement Therapy 62 IRX 2 62 mucositis 62 worsening thrombocytopenia 62 neutropenic patients 62 unresectable tumors 62 benign prostatic hypertrophy BPH 62 SUPPRELIN R LA 62 lupus erythematosus 62 diabetes mellitus DM 62 multicenter Phase 62 ergot derivatives 62 CP CPPS 62 Ph + acute lymphoblastic 62 CEQ# 62 Xanafide 62 mediated apoptosis 62 FASLODEX 62 ganciclovir 62 Myeloid 62 Patients Receiving 62 sensory neuropathy 62 PLX STROKE targeting 62 colesevelam HCl 62 hypercalcaemia 62 gastric adenocarcinoma 62 Dyskinesia 62 Humanized Anti 62 prostate cancer HRPC 62 vWD 62 leukemia CLL 62 painful diabetic neuropathy 62 Systemic Sclerosis 62 Quinamed 62 Lubiprostone 62 overactive bladder syndrome 62 NEBIDO VANTAS SUPPRELIN LA 62 Amgen Neulasta ® 62 selective A2A adenosine receptor 62 cervical intraepithelial neoplasia 62 opioid induced bowel dysfunction 62 Initiate Clinical Trial 62 mycosis fungoides 62 primary dysmenorrhea 62 leukotriene receptor antagonist 62 Chemotherapy induced 62 endotoxemia 62 Methylnaltrexone 62 accumulate preferentially 62 anaphylaxis dyspnea flushing 62 Dose Escalation 62 including cyclosporine methotrexate 62 sitaxsentan 62 IIa Clinical Trial 62 enterocolitis 62 failure NYHA 62 allogeneic bone marrow 62 SHPT 62 Hiberix 62 Allogeneic 62 Ganciclovir 62 thromboembolic events 62 Endometrial Cancer 62 LHRH receptor positive 62 cerebral vasospasm 62 gastrointestinal toxicities 62 r hGH 62 T1c 62 fallopian tube cancers 62 PKC# 62 pancreatic insufficiency 62 Chronic Myelogenous Leukemia 62 beta 1a 62 huC# DM4 62 patients undergoing percutaneous 62 TransVax ™ 62 LPS induced 62 psoriatic arthritis PsA 62 acadesine 62 Temsirolimus 62 recurrent NSCLC 62 malignant pleural mesothelioma MPM 62 juvenile idiopathic arthritis 62 cytopenias 62 bisoprolol 62 basal cell carcinoma BCC 62 AVASTIN 62 IL# PE#QQR 62 castrate resistant prostate cancer 62 Angiotensin Converting Enzyme 62 Dacogen injection 62 Noxafil 62 monoclonal anti 62 TYGACIL 62 Catena ® 62 Cytomegalovirus CMV 62 pharyngitis tonsillitis 62 Infusion reactions 62 Progressive Multifocal Leukoencephalopathy 62 epithelial tumors 62 Serostim ® 62 veno occlusive disease 62 cyclophosphamide methotrexate 62 Myelodysplasia 62 GVAX ® 62 constipation predominant irritable bowel 62 atopic disease 62 Indomethacin 62 Relapsed Multiple Myeloma 62 lupus nephritis 62 Peg IFN 62 Epidermal Growth Factor Receptor 62 Camptosar ® 62 OMNARIS HFA 62 pancreatic colorectal 62 HepaGam B TM 62 patients receiving myelosuppressive 62 Intranasal 62 herpetic keratitis 62 CYP#A# substrate 62 CIMZIA ™ 62 Escherichia coli Klebsiella pneumoniae 62 ® chorionic gonadotropin 62 headache nasopharyngitis 62 ACE Inhibitors 62 graft dysfunction 62 Luramist TM 62 Eculizumab 62 TRANSDUR ® 62 Traficet EN 62 Cloretazine 62 microsphere therapy 62 allograft rejection 62 relapsed leukemia 62 inhalation powder 62 Tyrosine Kinase Inhibitors 62 Neoadjuvant 62 Respiratory Syncytial Virus 62 IMPACT DCM 62 oncolytic virus therapies 62 Adjunctive 62 approved incretin mimetic 62 myalgia arthralgia 62 MALT lymphoma 62 Vaccine Recombinant 62 CYT# QbG# 62 NS5B polymerase 62 metformin accumulation 62 pulmonary exacerbations 62 cough dyspnea 62 relapsed CLL 62 acute myelogenous leukemia AML 62 stable angina pectoris 62 Multiple Myeloma MM 62 Study Shows Promise 62 recombinant PSMA vaccine 62 anthracycline containing 62 IV melanoma 62 Appears Safe 62 PPSV# 62 Ovitrelle R Serostim 62 Interferon beta 62 Central Retinal Vein 62 refractory chronic myeloid 62 TKB# 62 Interferon Beta 62 primidone 62 Improves Survival 62 immune thrombocytopenic purpura 62 Secondary endpoints include 62 Granted Orphan Drug 62 Vandetanib 62 chronic HCV infection 62 Heart Failure Patients 62 prostate cancer CaP 62 miconazole Lauriad ® 62 Syncria R 62 daily subcutaneous injections 62 advanced metastatic renal 62 LymphoStat B TM 62 Posaconazole 62 receiving INTRON 62 serum aminotransferase levels 62 CMV infection 62 carcinoma HCC 62 Subgroup Analysis